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ABSTRACT
Background. The use of areola-sparing (AS) or nipple-
areola-sparing (NAS) mastectomy for the treatment or risk
reduction of breast cancer has been the subject of
increasing dialogue in the surgical literature over the past
decade. We report the initial experience of a large com-
munity hospital with AS and NAS mastectomies for both
breast cancer treatment and risk reduction.
Methods. A retrospective chart review was performed of
patients undergoing either AS or NAS mastectomies from
November 2004 through September 2009. Data collected
included patient sex, age, family history, cancer type and
stage, operative surgical details, complications, adjuvant
therapies, and follow-up.
Results. Forty-three patients underwent 60 AS and NAS
mastectomies. Forty-two patients were female and one was
male. The average age was 48.7 years (range, 28–76 years).
Forty mastectomies were forbreastcancer treatment,and 20
were prophylactic mastectomies. The types of cancers
treated were as follows: invasive ductal (n = 19), invasive
lobular (n = 5), ductal carcinoma-in situ (n = 15), and
malignant phyllodes (n = 1). Forty-seven mastectomies
(78.3%) were performed by inframammary incisions. All
patients underwent immediate reconstruction with either
tissue expanders or permanent implants. There was a 5.0%
incidence of full-thickness skin, areola, or nipple tissue loss.
Theaveragefollow-upoftheserieswas18.5 months(range,
6–62 months). One patient developed Paget’s disease of the
areola 34 months after an AS mastectomy (recurrence rate,
2.3%). There were no other instances of local recurrence.
Conclusions. AS and NAS mastectomies can be safely
performed in the community hospital setting with low
complication rates and good short-term results.
The surgical treatment of breast cancer over the past
century has evolved from extensive disﬁguring procedures
to less invasive and cosmetically acceptable ones. The
development of an oncoplastic approach to patients with
newly diagnosed breast cancer means giving more con-
sideration to the cosmetic (‘‘plastic’’) outcomes as well as
maximizing oncologic (‘‘onco’’) safety. As the evolution-
ary process has continued, it is not surprising that one of
the long-held dogmas of mastectomy surgery (sacriﬁce of
the nipple-areola complex, NAC) would be challenged as
necessary for all women undergoing mastectomy.
The use of areola-sparing (AS) and nipple-areola-spar-
ing (NAS) mastectomy for the treatment or risk reduction
of breast cancer has been the subject of increasing dialogue
in the surgery literature over the past few decades.
1–18 The
primary concerns raised about the preservation of the are-
ola and nipple are: (1) missing occult cancers in the nipple
and/or areola; (2) having an increased risk of subsequent
new or recurrent cancers in the retained NAC; and (3)
partial or complete necrosis of the NAC.
Most reports on nipple-sparing mastectomy (NSM) have
come from academic medical centers. Yet in the United
States, approximately 85% of cancer care is delivered at
the community level.
19,20 If there is to be real traction for
NSM to gain wider acceptance, then the adoption of this
technique at the community level of cancer care would be
important. Because most breast cancer care is at the com-
munity level, this setting is a rich source of short- and long-
term data of patients undergoing NSMs. The goal of this
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NAS mastectomies, with immediate ﬁrst-stage recon-
structions, in the community setting.
MATERIALS AND METHODS
After obtaining institutional review board authorization,
we retrospectively reviewed the charts of 43 patients who
underwent either AS or NAS mastectomies from Novem-
ber 2004 through September 2009. The following patient
data was collected: sex, age, family history, medical his-
tory, cancer type and stage, operative surgical details,
complications, adjuvant and neoadjuvant therapies, and
follow-up.
Preoperatively, all patients underwent digital mammo-
grams, high-resolution breast ultrasound, and breast
magnetic resonance imaging. All cases were presented to a
weekly preoperative multidisciplinary breast conference.
No patients with clinical or imaging evidence of NAC
involvement by their cancers or with locally advanced or
inﬂammatory breast cancer were considered for the AS or
NAS mastectomy. In addition, patients with lymph node
involvement, those undergoing neoadjuvant chemotherapy,
and those needing postoperative radiotherapy were con-
sidered for AS or NAS mastectomy.
The choice of mastectomy for cancer treatment was dri-
ven by patient choice, extent of cancer in the breast, and
multicentric disease. All mastectomies in this series were
performed by one surgeon (J.K.H.), and 85% of the recon-
structions were performed by one plastic surgeon (A.H.S.).
Surgical Technique
An AS or NAS mastectomy is a skin-sparing mastec-
tomy (SSM) with preservation of the areola or nipple and
areola, respectively. Our current technique is to remove the
breast tissue by means of two incisions, one in the axilla
and the other in the inframammary fold. The axillary
incision is used for two aspects of the procedure. The ﬁrst
is the sentinel lymph node biopsy and/or axillary lymph
node dissection, and the second is the dissection of the
axillary tail and upper third of the breast. The breast is
dissected off the pectoralis fascia in the upper third con-
necting with the same dissection from the inframammary
fold. The dissection of the axillary tail is along the anterior
mammary fascia medially, centrally, and caudally and
assures that the entire axillary tail is resected.
In the inframammary fold, a 12- to 14-cm incision is
used. The initial maneuver from the inframammary fold is
to free the breast from the pectoralis fascia. After this, the
anterior mammary fascia is identiﬁed (Fig. 1) and the
dissection is carried along this plane dividing the individual
Cooper’s ligaments with scissors under the dermis (Fig. 1).
This dissection preserves most of the subcutaneous fat
layer, which in turn preserves the subdermal and subcuta-
neous fat blood vessels. No tumescent injections are used
to facilitate the dissection.
In the area of the cancer, the subcutaneous fat is thinned
to the level of the superﬁcial fascia under the dermis
(Fig. 2). In some instances, all subcutaneous fat and the
superﬁcial fascia down to the dermis are excised, and when
the cancer involves the anterior mammary fascia, the
subdermal dissection is used. If there is extension of the
cancer through the anterior mammary fascia into the sub-
cutaneous fat, the overlying skin is excised. Intraoperative
high-resolution ultrasound is used with invasive cancers to
mark the skin in the area of the tumor.
The subcutaneous fat layer of the breast disappears
under the NAC. If breast tissue is found adherent to the
underside of the areola, then it is dissected free. The base of
the nipple is divided sharply, and the area where the base of
the nipple is divided is marked with a short silk suture on
the mastectomy specimen. In all cases, the nipple papilla is
cored out or a deep sample of the nipple base is taken
during biopsy. No breast tissue is left under the areola and
nipple. Biopsy samples of the nipple base are evaluated
with permanent histology, not via frozen sections.
FIG. 1 Artist drawing depicting the anterior mammary fascia
(AMF), retromammary fascia (RMF), Cooper’s ligaments (CL), and
terminal ductal lobular unit (TDLU). Also depicted is the premam-
mary (PM) or subcutaneous fat zone. The retromammary zone (RM)
is deep to the glandular tissue. The mammary zone (MZ) contains
central ducts and most of the peripheral ducts and lobules. The
lactiferous sinus (LS) is the dilated end of a lobar duct. (Reproduced
with permission from Kuerer HM, ed. Breast Surgical Oncology. New
York: McGraw-Hill Medical, 2010)
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lymphnodeprocedures,allpatientsunderwentreconstruction
with the placement ofeithera tissueexpanderor a permanent
implant. Figure 3 shows the pre- and postoperative photos of
a patient who underwent bilateral NAS mastectomies.
RESULTS
Forty-three patients (42 women, 1 man) underwent 60
AS (n = 17) or NAS (n = 43) mastectomies. Forty mas-
tectomies were performed for cancer treatment, and 20
mastectomies were prophylactic. The average patient age
was 48.7 years (range, 28–76 years). Eighteen (42%) of 43
patients had a family history for breast cancer, including 6
patients who were BRCA1/2 gene positive. Patient medical
histories included existing heart disease (n = 2), hyper-
tension (n = 7), diabetes mellitus (n = 4), history of stroke
(n = 1), and smoking (n = 4).
The types of breast cancers treated were 19 invasive
ductal carcinomas, 15 ductal carcinoma-in situ, 5 invasive
lobular carcinomas, and 1 malignant phyllodes tumor. A
summary of the pathology grades and tumor sizes is listed in
Table 1. The ﬁnal pathologic stages of our patients are
depicted in Table 2. No patient had positive nipple biopsy
ﬁndings.Ofthe6patientswhowereBRCA1/2genepositive,
1 patient had bilateral prophylactic NAS mastectomies,
whereastheother5patientshadsubsequentprophylacticAS
or NAS mastectomies after their initial mastectomies for
their primary cancers.
Tumormarkersweredeterminedonallcancersexceptfor
the one patient who had a malignant phyllodes tumor.
Twenty-one patients were estrogen receptor and/or proges-
terone receptor positive, 9 were HER-2/neu positive, and 6
were triple negative. Eight patients underwent neoadjuvant
chemotherapy, 13 underwent adjuvant chemotherapy, 21
received adjuvant antiestrogen therapy, and 11 received
FIG. 2 Artist drawing of the
cross-sectional anatomy of the
breast showing important
landmarks. (Reproduced with
permission from Kuerer HM,
ed. Breast Surgical Oncology.
New York: McGraw-Hill
Medical, 2010)
Areola and Nipple-Areola-Sparing Mastectomy 919postoperative radiotherapy to their mastectomy sites, axil-
lae, and supraclavicular regions.
Forty-seven mastectomies (78.3%) were performed by
inframammary incisions. Eleven radial incisions and two
nonradial incisions were used for the remaining 21.7% of
the mastectomies. These 13 patients had previously
undergone either partial mastectomies or breast biopsies, or
they had an indication to achieve breast symmetry.
Superﬁcial skin, areola, and nipple slough occurred in 6
(10%) of our 60 mastectomies. All of these healed in
2 weeks with only slight depigmentation of the nipple or
areola. The more serious complication of full-thickness
loss of skin, nipple, or the NAC occurred in 3 patients
(5%). The patient with the nipple-areola loss had under-
gone a 6 9 3 cm wide area of subdermal fat thinning
adjacent to the areola because of tumor proximity. The
nipple areolar eschar was excised, the expander was
removed, and the breast was reconstructed in stages at a
later date. The second patient with nipple necrosis healed
spontaneously in 2 months; a ﬂat scar was left. The third
patient who had the mastopexy as part of the NAS mas-
tectomy had diabetes. The ischemic corners of the medial
and the lateral mastopexy ﬂaps were debrided, and the
wound was allowed to heal in secondarily for a delayed
implant exchange. Other complications included postop-
erative bleeding (n = 1) and infection (n = 2). The two
patients with infected tissue expanders and the one with
necrosis of the NAC required unplanned removal of their
expanders. No complications occurred in the 11 patients
who underwent postoperative adjuvant radiotherapy.
The average follow-up time of the series was
18.5 months (range, 6–62 months). One patient (2.3%)
developed a recurrent cancer, which was Paget’s disease of
the areola, 34 months after an AS mastectomy. This was
treated with resection of the areola. At pathologic review,
the nipple was found to be not involved with ductal car-
cinoma-in situ at the time of her AS mastectomy. There
have been no other instances of local recurrences.
DISCUSSION
The concept of the NSM was popularized by Freeman in
the 1960 s and 1970s.
21 The procedure was referred to as a
subcutaneous mastectomy. Breast tissue was left along the
undersurface of the NAC to protect the blood supply to the
nipple and areola. Many patients underwent these proce-
dures at the Mayo Clinic in Rochester, Minnesota, for
approximately 20 years. Subsequently, Hartmann et al.
published the follow-up data on these patients from the
Mayo Clinic and found that prophylactic subcutaneous
mastectomy did have a protective beneﬁt by reducing the
risk of breast cancer in both high-risk and moderate-risk
groups by 81–94%.
22 In their later study, which was based
on the same patient population, a similar risk reduction was
found in patients with BRCA1 or BRCA2 gene mutations.
23
However, the subcutaneous mastectomy fell out of favor in
the United States.
FIG. 3 Pre- and postoperative photos of a 54-year-old patient who
underwent bilateral nipple-areola-sparing mastectomies via infra-
mammary and axillary incisions
TABLE 1 Pathology
Disease HG IG LG Average size (cm) Size range (cm)
IDC 10 7 2 2.4 1.0–5.0
ILC 2 1 2 3.3 1.0–7.5
DCIS 6 8 1 1.9 1.0–4.5
HG high grade, IG intermediate grade, LG low grade, IDC invasive
ductal carcinoma, ILC invasive lobular carcinoma, DCIS ductal car-
cinoma-in situ
TABLE 2 AJCC cancer stage
AJCC stage
0 1 234
No. of patients 14 11 6 7 1
AJCC American Joint Committee on Cancer
920 J. K. Harness et al.The use of NSM for the treatment of breast cancer grew
in the 1970 s and 1980s.
24,25 In 2003, Gerber, Krause, and
colleagues from Germany reported their experience with
NSM.
1 At 59 months, there were 6 recurrences (5.4%) in
the 112 NSMs and 11 recurrences (8.2%) among the 134
women who had the NAC removed with their mastecto-
mies.
1 After the report by Gerber et al., other single
institutions have reported their experience with NSMs.
2–18
A review article by Voltura et al. found local recurrence
rates with NSM showed an equivalency to SSM.
7 They
thought that patients undergoing neoadjuvant chemother-
apy were acceptable candidates for NSM. They did not
core out the nipple. Their selection criteria included tumors
B4.5 cm that were also C2.5 cm from the edge of the
areola. They excluded patients with bloody nipple dis-
charge, inﬂammatory breast cancer, or tumor involvement
of the NAC.
Garcia-Etienne et al. found that in properly selected
cases local control after NSM is consistent with that of total
standard mastectomy and SSM.
8 They stated an opinion
that local failure is a manifestation of tumor biology rather
than preservation of the NAC. They reviewed 1826 NSMs
performed for breast cancer treatment published in the
recent literature and found only three local recurrences
(0.16%) within the NAC.
6,14,16 They thought that preop-
erative evaluation for NSM should include complete
imaging studies, preferably breast magnetic resonance
imaging. They included in their selection criteria tumor
size of up to 5 cm and a tumor to nipple distance of C2 cm.
Rusby et al. have published the most recent review of
NSM in the literature.
12 They also found recurrence rates of
\5% in properly selected patients undergoing NSM for
breast cancer treatment. The incidence of cancer in the
retained nipple after risk-reducing mastectomy is \1%.
Nipple necrosis rates were 8 and 16% for total and partial
necrosis, respectively. They also reviewed some of the
literature on terminal ductal lobular units in the nipple. The
incidence was reported to be between 9% and 17%, with
most of the terminal ductal lobular units at the base of the
nipple papilla.
26 They cautioned against ﬁxed-volume
reconstructions after NSM because of a higher incidence of
NAC necrosis.
The major limitations of our series are the limited
numbers of cases and short follow-up. However, compar-
ing our initial series of 43 patients with 60 AS or NAS
mastectomies with the published literature showed many
similarities. We have treated the full spectrum of breast
cancer, excluding patients with locally advanced or
inﬂammatory tumors as well as those involving the NAC.
Only 2 patients (3.3%) had full-thickness nipple/areola
loss because we saved the NAC. Our results compared
favorably with those of the published literature on NAC
loss.
7,8,12
The 11 patients who underwent postoperative adjuvant
radiotherapy had no complications. This experience par-
allels our outcomes with SSM who had ﬁrst-stage
reconstructions with tissue expanders. With both NSM and
SSM, we replace the tissue expanders with either saline or
silicone implants 4 months after the completion of
radiotherapy.
In our series, we have had only one case of local
recurrence of breast cancer. The recurrence was Paget’s
disease of the areola diagnosed 34 months after an AS
mastectomy. The patient was treated with resection of her
areola and has had no further recurrence of cancer
13 months later. Our short-term recurrence rate compares
favorably with similar series in the literature.
2,7
Our initial experience with AS or NAS mastectomies in
the community setting has taught us several things. First,
the performance of NSM can be effectively accomplished
in the community setting. This procedure requires a team
effort. Determining suitability for NSM is a joint process
between the breast and the plastic surgeon. Patients with
moderate to marked ptosis were not excluded because we
perform a modiﬁed mastopexy to correct the ptosis as part
of the NSM mastectomy.
In our series, inclusion criteria for NSM are nearly the
same as those for SSM (multicentric disease, extent of
disease too large for breast conservation, and patient
choice). Exclusion criteria for NSM in our series included
inﬂammatory breast cancer, involvement of the NAC, and
locally advanced breast cancers.
The high viability rate of the NAC is likely the result of
three factors. First, we use primarily inframammary inci-
sions that spare the medial and lateral vessels supplying the
skin of the breast. Second, the subcutaneous fat plane of the
breast is preserved, which then preserves the microcircu-
lation of the breast skin and areola. The subcutaneous fat
layer is only thinned in the area of the cancer. Third, most
of the reconstructions were performed with tissue
expanders and not ﬁxed-volume implants or autologous
ﬂaps, which create increased pressure in the subcutaneous
space.
In conclusion, NSM can be safely performed in the
community hospital setting with low complication rates
and good short-term results. The inframammary approach
for NSM in our hands has been a safe and reliable proce-
dure that does not adversely affect the viability of the
NAC. In addition, our experience with the inframammary
approach results in less visible scars, which we think pro-
vides better aesthetic results.
We have adopted the following indications and contra-
indications for NSM: indications are candidates for SSM
and patient choice, and contraindications are involvement
of the NAC, and presence of inﬂammatory and locally
advanced breast cancers.
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